Catheterization and Cardiovascular Interventions
Volume 100, Issue 6 pp. 1132-1133
COMMENTARY

Data are data: Do we need a randomized trial of transcatheter aortic valve replacement for bicuspid valves?

Hiroki Ueyama MD, 

Hiroki Ueyama MD

Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA

Search for more papers by this author
Peter C. Block MD, FACC, MSCAI, 

Corresponding Author

Peter C. Block MD, FACC, MSCAI

Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA

Correspondence: Peter C. Block, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.

Email: [email protected]

Search for more papers by this author
First published: 29 November 2022
https://doi.org/10.1002/ccd.30479

Expert Article Analysis for: Trends, predictors, and outcomes of transcatheter aortic valve implantation in patients with bicuspid aortic valve related disease: Insights from the Nationwide Inpatient Sample and Nationwide Readmission Database

Key Points

  • No randomized trials have been done for TAVR in bicuspid aortic valve (BAV) and probably will never be done.

  • TAVR for BAV has a similar risk profile to tricuspid aortic valve patients except for a higher risk of permanent pacemaker implantation at 30 and 180 days after the index procedure.

  • Further real-world data are needed to refine patient selection, procedural technique, and lifetime planning of intervention.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.